Focused On-demand Library for Maleylacetoacetate isomerase

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
O43708

UPID:
MAAI_HUMAN

ALTERNATIVE NAMES:
GSTZ1-1; Glutathione S-transferase zeta 1

ALTERNATIVE UPACC:
O43708; A6NED0; A6NNB8; A8MWD7; B2RCK3; O15308; O75430; Q6IB17; Q7Z610; Q9BV63

BACKGROUND:
The enzyme Maleylacetoacetate isomerase, with its alternative identities GSTZ1-1 and Glutathione S-transferase zeta 1, is integral to metabolic processes. It showcases limited glutathione-conjugating activity against specific substrates and functions as a maleylacetoacetate isomerase. Its activity extends to low glutathione peroxidase functionality, facilitating the glutathione-dependent transformation of certain hydroperoxides and acids.

THERAPEUTIC SIGNIFICANCE:
Associated with Maleylacetoacetate isomerase deficiency, this enzyme's dysfunction leads to a benign metabolic condition detectable by newborn screening. The exploration of Maleylacetoacetate isomerase's role could pave the way for innovative therapeutic approaches, enhancing our understanding of metabolic diseases and guiding the creation of novel treatment options.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 7812 of 8789